Kuros Biosciences commenced full launch of MagnetOs™ bone graft substitute granules, available as a moldable putty to fill bony defects. In early phased launch, first commercial uses of MagnetOs occurred in 2018 in the U.S. and U.K., in spinal fusion and scoliosis procedures, respectively.
MagnetOs biphasic calcium phosphate graft is designed to mimic the porous, trabecular structure of cancellous bone. Its needle-shaped submicron surface topography was developed to attach and spread macrophages and optimize osteoimmunology to deliver uniform, reliable fusion equivalent to the gold standard, autograft.
Unlike osteoconductive bone grafts, which may lead to fibrous tissue and scarring, bone forms throughout MagnetOs simultaneously, without added cells or growth factors.
In addition to the launch of MagnetOs, Kuros introduced KUR-113 Fibrin-PTH technology to the spine market. Earlier this month, Kuros gained FDA approval for its Investigational New Drug (IND) application to initiate a Phase IIA clinical trial to evaluate KUR-113 in single-level transforaminal lumbar interbody fusion to treat degenerative disc disease, with autograft as comparator.
This IND application is considered to be the first ever approval by FDA to evaluate a drug/biologic combination product candidate for lumbar interbody fusion.
Kuros Biosciences commenced full launch of MagnetOs™ bone graft substitute granules, available as a moldable putty to fill bony defects. In early phased launch, first commercial uses of MagnetOs occurred in 2018 in the U.S. and U.K., in spinal fusion and scoliosis procedures, respectively.
MagnetOs biphasic calcium phosphate graft is designed...
Kuros Biosciences commenced full launch of MagnetOs™ bone graft substitute granules, available as a moldable putty to fill bony defects. In early phased launch, first commercial uses of MagnetOs occurred in 2018 in the U.S. and U.K., in spinal fusion and scoliosis procedures, respectively.
MagnetOs biphasic calcium phosphate graft is designed to mimic the porous, trabecular structure of cancellous bone. Its needle-shaped submicron surface topography was developed to attach and spread macrophages and optimize osteoimmunology to deliver uniform, reliable fusion equivalent to the gold standard, autograft.
Unlike osteoconductive bone grafts, which may lead to fibrous tissue and scarring, bone forms throughout MagnetOs simultaneously, without added cells or growth factors.
In addition to the launch of MagnetOs, Kuros introduced KUR-113 Fibrin-PTH technology to the spine market. Earlier this month, Kuros gained FDA approval for its Investigational New Drug (IND) application to initiate a Phase IIA clinical trial to evaluate KUR-113 in single-level transforaminal lumbar interbody fusion to treat degenerative disc disease, with autograft as comparator.
This IND application is considered to be the first ever approval by FDA to evaluate a drug/biologic combination product candidate for lumbar interbody fusion.
Copy to clipboard 
